フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now...
Annual General Meeting of Active Biotech AB The Annual General Meeting of Active Biotech was held on May 19, 2022. Due to the situation...
FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today...
Annual Report 2021 Active Biotech AB (publ) Active Biotech's Annual Report 2021 is now available for download at www.activebiotech.com. The...
Active Biotech strengthens the patent protection for laquinimod in eye disorders Lund, April 26, 2022, Active Biotech (NASDAQ STOCKHOLM:...
Active Biotech Interim Report Q1 2022 FIRST QUARTER IN BRIEF Dr. Erik Vahtola appointed Chief Medical Officer (Jan 01)First patient dosed in...
Active Biotech: NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS The shareholders of Active Biotech AB (publ) are invited to the Annual...
Number of shares and votes in Active Biotech The number of shares and votes in Active Biotech has changed as a result of allotment of...
Correction: Active Biotech Year End Report 2021 The correction refers to the administrative costs for the period January – December 2021 that...
Active Biotech: Year End Report 2021 FOURTH QUARTER IN BRIEF In 2021, we made substantial progress in our projects to address unmet medical...
Active Biotech enters into global patent license agreement with Oncode Institute for tasquinimod in myelofibrosis Lund, February 9, 2022...
Active Biotech announces first patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma Lund...
Active Biotech Appoints Erik Vahtola as Chief Medical Officer Lund, January 4, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announced today...
Preclinical tasquinimod data presented at ASH 2021 available on Active Biotech’s website Lund, December 15, 2021 - Active Biotech (NASDAQ...
Active Biotech's nomination committee appointed In accordance with a decision made by the Annual General Meeting held on May 19, 2021...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約